Targeted therapies in development for non-small cell lung cancer

@inproceedings{Reungwetwattana2013TargetedTI,
  title={Targeted therapies in development for non-small cell lung cancer},
  author={Thanyanan Reungwetwattana and Grace Kho Dy},
  booktitle={Journal of carcinogenesis},
  year={2013}
}
The iterative discovery in various malignancies during the past decades that a number of aberrant tumorigenic processes and signal transduction pathways are mediated by "druggable" protein kinases has led to a revolutionary change in drug development. In non-small cell lung cancer (NSCLC), the ErbB family of receptors (e.g., EGFR [epidermal growth factor receptor], HER2 [human epidermal growth factor receptor 2]), RAS (rat sarcoma gene), BRAF (v-raf murine sarcoma viral oncogene homolog B1… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…